获取途径

作者

Jiazhuo Tang Yang Fu Yuxiao Song Jiaxin Yin Jun Wang Hugo Arasanz Bicheng Zhang

作者单位

Cancer Center，Renmin Hospital of Wuhan University，Wuhan，China；Department of Oncology，Xiangyang Hospital，Hubei University of Chinese Medicine，Xiangyang，China；Cancer Center，Renmin Hospital of Wuhan University，Wuhan，China；Department of Oncology，Xiangyang Hospital，Hubei University of Chinese Medicine，Xiangyang，China；Department of Oncology，The First Affiliated Hospital of Shandong First Medical University，Jinan，China；Department of Medical Oncology，Hospital Universitario de Navarra，Navarra Medical Research Institute (IdiSNA)，Pamplona，Spain；Oncobiona Group，Navarrabiomed，Navarra Medical Research Institute (IdiSNA)，Pamplona，Spain；Cancer Center，Renmin Hospital of Wuhan University，Wuhan，China

刊名

胸部疾病杂志

年份

2024

卷号

第16卷

期号

第5期

页码

3251-3259

关键词

Complement component 1q (C1q) non-small cell lung cancer (NSCLC) immune checkpoint inhibitors (ICIs) survival Eastern Cooperative Oncology Group performance status (ECOG-PS)

摘要

BackgroundThere is a lack of readily available clinical markers of non-small cell lung cancer immunotherapy efficacy. Previous studies have found that overexpressed complement component 1q promotes macrophage M2 polarization and an immunosuppressive tumor microenvironment. This study aimed to evaluate the association between serum C1q and the efficacy of immune checkpoint inhibitors in patients with advanced NSCLC.MethodsA total of 168 patients with advanced NSCLC who received ICIs in the Ren...更多

BackgroundThere is a lack of readily available clinical markers of non-small cell lung cancer immunotherapy efficacy. Previous studies have found that overexpressed complement component 1q promotes macrophage M2 polarization and an immunosuppressive tumor microenvironment. This study aimed to evaluate the association between serum C1q and the efficacy of immune checkpoint inhibitors in patients with advanced NSCLC.MethodsA total of 168 patients with advanced NSCLC who received ICIs in the Renmin Hospital of Wuhan University were included in this study. Serum C1q levels were collected before and 3 weeks after immunotherapy treatment, together with other data on clinical and demographic characteristics. The primary outcome was overall survival . Secondary outcome was progression-free survival [defined as months from first dose of ICIs to clinical or radiographic progression by Response Evaluation Criteria in Solid Tumors version 1.1 or death, censored at date of last follow-up] and objective response rate which was defined as rate of complete response or partial response at best response by RECIST 1.1.ResultsA total of 168 patients were included in this study, including 127 males and 41 females . Thirty-nine patients achieved objective response , and 111 patients had stable disease as best response. The ORR was 23.21% and the disease control rate was 89.28%. The upward trends of serum C1q levels between baseline and post-treatment were strongly associated with the shorter PFS [hazard ratio =1.554, 95% confidence interval : 1.07–2.10, P=0.01] and OS . Moreover, taking the median OS 18.9 months as the cut-off of prognosis, receiver operating characteristic analysis showed that serum baseline C1q yielded an area under the ROC curve of 0.785 . The optimal serum baseline C1q cut-off point to predict immunotherapy prognosis was 216.2 mg/L.ConclusionsThese findings suggested that elevated serum C1q after ICIs treatment was related to a worse prognosis in NSCLC. Monitoring the baseline and dynamic data of C1q during hospitalization showed the potential to predict the prognosis of NSCLC patients.收起

基金

国家自然科学基金

文献类型

期刊